Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE. -- Ignore unavailable to you. Want to Upgrade?

To: gcrispin who wrote (132)	6/5/1999 2:44:00 PM
From: Arthur Radley	Respond to of 182

Howdy Partner! Thanks for the info. I agree that if these test prove out, regular dentist will be able to keep more of this business "in-house". What is so positive about this IMO is that so many patients never follow-up with the periodontist when they are referred to by the dentist. Isn't if fair to assume that when the dentist tells the potential patient for a visit to a perio what is involved(SRP) that they never follow-up with an appointment? With this treatment option available to the regular dentist, this should enhance the use of Atridox IMO. Certainly was nice to see the pop up this week in share prices. Hope it continues in the coming weeks. I have a sneaking suspicion that with this increasing volume we have some people "in the know" taking a position in the stock because of revenue numbers coming out for this quarter. Always nice to dream!(:>)